OncLiveDr. Spratt on Combination of Immunotherapy and Radiation in Prostate CancerOncLiveDaniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses the combination of immunotherapy and radiatio… Continue reading
TechCrunch |
Weekly Roundup: CRISPR-Cas9 patent case concludes, Mark Zuckerberg’s 5000 word letter to global community
TechCrunch This week, the CRISPR-Cas9 patent case came to a close, an encrypted messaging app went open source and Facebook announced some big changes to its video product. These are some of the notable stories in tech from this week. You can also receive … |
2 Minute Medicine |
Shortened dose of immunotherapy ineffective in allergic rhinitis
Healio “International guidelines regarding immunotherapy recommend a minimum of 3 years of treatment with both [subcutaneous or sublingual] delivery methods. If a 2-year regimen had demonstrated long-term benefits in addition to efficacy, this could have … Sublingual grass pollen immunotherapy not effective for moderate-severe seasonal allergic rhinitis2 Minute Medicine |
Undark Magazine |
Abstracts: Disappearing Karst, Crispr, and More
Undark Magazine The U.S. Patent and Trademark Office ruled in favor of the Broad Institute Wednesday, allowing the Harvard and MIT-affiliated research center to retain rights to dozens of Crispr-Cas9 patents. (New York Times). • Abalone graveyards are the result of … |
|
Global Synthetic Biology Market to Expand at 32.60% CAGR till 2019 Thanks to Growing R&D Efforts
Satellite PR News (press release) The global synthetic biology market is projected to grow remarkably, says a report from Transparency Market Research (TMR). This report is titled “Synthetic Biology Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019”. |
Nature.com |
Why the CRISPR patent verdict isn’t the end of the story
Nature.com It ruled that the Broad Institute of Harvard and MIT in Cambridge could keep its patents on using CRISPR–Cas9 in eukaryotic cells. That was a blow to the University of California in Berkeley, which had filed its own patents and had hoped to have the … Who should be allowed to use CRISPR?Popular Science UC Berkeley suffers big loss in CRISPR patent fight: What’s next for the powerful gene-editing technology?Los Angeles Times CRISPR patent dispute ends well for Broad Institute. Berkeley says: Not so fastThe Biological SCENE Seeking Alpha –Forbes –Scientific American –UC Berkeley News – University of California, Berkeley all 142 news articles » |